Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06219941
Registration number
NCT06219941
Ethics application status
Date submitted
21/11/2023
Date registered
23/01/2024
Date last updated
30/09/2026
Titles & IDs
Public title
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Query!
Scientific title
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)
Query!
Additional trial identifiers [1]
0
0
D9800C00001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Gastric Cancer
0
0
Query!
Gastroesophageal Junction Cancer
0
0
Query!
Biliary Tract Cancer
0
0
Query!
Pancreatic Ductal Adenocarcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Stomach
Query!
Cancer
0
0
0
0
Query!
Biliary tree (gall bladder and bile duct)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - AZD0901
Treatment: Drugs - 5-Fluorouracil
Treatment: Drugs - Leucovorin
Treatment: Drugs - l-leucovorin
Treatment: Drugs - Irinotecan
Treatment: Drugs - Nanoliposomal Irinotecan
Treatment: Drugs - Gemcitabine
Experimental: Sub Study 1 - AZD0901 MONOTHERAPY - Sub Study 1 will investigate AZD0901 monotherapy in order to evaluate the safety, tolerability, and efficacy of AZD0901.
Experimental: Sub Study 2 - AZD0901 IN COMBINATION WITH ANTI-CANCER AGENTS IN PANCREATIC DUCTAL ADENOCARCINOMA - Substudy 2 will investigate the safety and efficacy of AZD0901 as first line systemic treatment used in combination with different chemotherapy agents
Experimental: Sub Study 3: AZD0901 MONOTHERAPY IN BILIARY TRACT CANCER - Substudy 3 Further evaluate the preliminary anti-tumour activity of AZD0901 monotherapy by assessment of DRR.
Treatment: Drugs: AZD0901
Antibody-drug conjugate/Biologic
Treatment: Drugs: 5-Fluorouracil
Chemotherapy agents
Treatment: Drugs: Leucovorin
Chemotherapy agents
Treatment: Drugs: l-leucovorin
Chemotherapy agents
Treatment: Drugs: Irinotecan
Chemotherapy agents
Treatment: Drugs: Nanoliposomal Irinotecan
Chemotherapy agents
Treatment: Drugs: Gemcitabine
Chemotherapy agents
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
Query!
Assessment method [1]
0
0
To investigate the safety and tolerability, of AZD0901 monotherapy or in combination with anti-cancer agents in particpants with advanced or metastatic solid tumours expressing CLDN18.2.
Query!
Timepoint [1]
0
0
30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
Query!
Primary outcome [2]
0
0
Objective Response Rate (ORR).
Query!
Assessment method [2]
0
0
Proportion of participants with a confirmed Complete Response (CR) or Partial Response (PR) as determined by the Investigator at local site as per RECIST v1.1.
Query!
Timepoint [2]
0
0
From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
The analysis will include all dosed/randomised participants as assigned/randomised. All deaths will be included, regardless of whether the participant withdraws from therapy or receives another anticancer therapy.
Query!
Timepoint [1]
0
0
From date of first dose/randomisation until the date of death due to any cause (approximately 2 years).
Query!
Secondary outcome [2]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [2]
0
0
Progression-free survival is defined as the time date of randomisation or enrollment until progression per RECIST v1.1 as assessed by the Investigator at local site, or death due to any cause, regardless of whether the participant withdraws from randomized therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST v1.1 progression.
Query!
Timepoint [2]
0
0
From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 2 years).
Query!
Secondary outcome [3]
0
0
Duration of Response (DoR)
Query!
Assessment method [3]
0
0
The time from the date of first documented confirmed response until date of first documented progression per RECIST v1.1 or death due to any cause.
Query!
Timepoint [3]
0
0
From the date of first documented confirmed response until date of documented progression (approximately 2 years).
Query!
Secondary outcome [4]
0
0
Disease control rate (DCR)
Query!
Assessment method [4]
0
0
The percentage of participants who have a confirmed CR or PR or who have SD per RECIST v1.1 as assessed by the Investigator at local site and derived from the raw tumour data up to 11 weeks after date of first dose/randomisation.
Query!
Timepoint [4]
0
0
Up to 11 weeks post date of first dose/randomisation
Query!
Secondary outcome [5]
0
0
Percentage change in tumor size
Query!
Assessment method [5]
0
0
The best percentage change from baseline in tumor size is the largest decrease (or smallest increase) from baseline for a participant, using RECIST v1.1 assessments.
Query!
Timepoint [5]
0
0
From start through to study completion.
Query!
Secondary outcome [6]
0
0
Serum concentration of AZD0901 (total ADC), total antibody (conjugated and unconjugated) and total unconjugated MMAE
Query!
Assessment method [6]
0
0
To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2.
Query!
Timepoint [6]
0
0
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
Query!
Secondary outcome [7]
0
0
Serum PK parameters of AZD0901, total antibody (conjugated and unconjugated) and MMAE including but not limited to AUC, Cmax, tmax, clearance and half-life, as data allow.
Query!
Assessment method [7]
0
0
To characterise the PK of AZD0901 monotherapy or in combination with anti cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2.
Query!
Timepoint [7]
0
0
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
Query!
Secondary outcome [8]
0
0
Clinical activity by baseline and/or on-treatment tissue-based biomarkers including, but not limited to, gene expression, mutation profiles, DNA damage, protein expression, immune response and/or mechanisms of resistance.
Query!
Assessment method [8]
0
0
To investigate baseline and/or on-treatment tissue-based RNA, DNA, and/or proteins, and association with clinical activity of AZD0901 (substudy 1).
Query!
Timepoint [8]
0
0
From date of first dose of AZD0901 up to 7 weeks.
Query!
Secondary outcome [9]
0
0
ADA status will be determined along with prevalence and incidence of anti-drug antibodies to AZD0901, and titer established.
Query!
Assessment method [9]
0
0
To determine the immunogenicity of AZD0901 monotherapy or in combination with anti-cancer agents in participants with advanced or metastatic solid tumours expressing CLDN18.2.
Query!
Timepoint [9]
0
0
From date of first dose of AZD0901 up until 90 days post AZD0901 discontinuation.
Query!
Eligibility
Key inclusion criteria
The list below is a summarised eligibility criteria for the study - refer to the study protocol for full criteria.
Master Inclusion Criteria applicable to all sub studies:
* Participant must be = 18 years or the legal age of consent at the time of signing the ICF.
* Participants who are CLDN18.2 positive.
* Must have at least one measurable lesion according to RECIST v1.1.
* ECOG performance status of 0 to 1 with no deterioration over the previous 2 weeks prior first day of dosing.
* Predicted life expectancy of = 12 weeks.
* Adequate organ and bone marrow function as defined by protocol.
* Body weight > 35 kg.
* Participants are willing to comply with contraception requirements.
Sub study 1 Specific Inclusion criteria:
* Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction.
* Advanced or metastatic GC/GEJC.
* Maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.
Sub study 2 Specific Inclusion criteria:
* Participants diagnosed with histologically confirmed metastatic or advanced PDAC.
* Availability of an archival sample or a fresh tumour biopsy taken at screening.
* No prior treatments for unresectable or metastatic disease. Prior neoadjuvant/adjuvant chemotherapy is permitted as long as participants progressed = 6 months (183 days) from the last dose.
Sub study 3 Specific Inclusion criteria
* Histologically confirmed, unresectable advanced, or metastatic adenocarcinoma of biliary tract, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder carcinoma (NOTE: Ampullary cancers are not eligible).
* Documented radiographic or clinical disease progression on or after at least one prior regimen and maximum 2 prior lines of systemic treatment for unresectable or metastatic disease.
Master
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
Exclusion Criteria applicable to all sub studies:
* Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
* Participants with clinically significant ascites that require drainage.
* A history of drug-induced non-infectious ILD/pneumonitis.
* Central nervous system metastases or CNS pathology.
* Peripheral neuropathy, sensory, or motor = Grade 2 at screening.
* History of another primary malignancy.
* Prior exposure to any MMAE-based ADC.
* Prior exposure to any CLDN18.2 targeted agents except anti-CLDN18.2 monoclonal antibody.
Sub study 1 Specific Exclusion criteria:
* Participants with HER2-positive (3+ by IHC, or 2+ by IHC, and positive by ISH) or indeterminate GC/GEJC unless they have failed/not tolerated/or are not eligible for standard anti-HER2 therapy, where available.
* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
* The use of concomitant medications known to prolong the QT/QTc interval.
Sub study 2 Specific Exclusion criteria:
* Known DPD enzyme deficiency based on local testing where testing is SoC.
* Use of strong inhibitor or inducer of UGT1A1.
* Use of strong inhibitors or inducers of CYP3A4.
* Known homozygous for the UGT1A1*28 allele based on local testing where testing is SoC.
Sub study 3 Specific Exclusion criteria
• Clinically significant biliary obstruction that has not resolved before enrollment.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
13/12/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
28/06/2027
Query!
Actual
Query!
Sample size
Target
226
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Melbourne
Query!
Recruitment hospital [2]
0
0
Research Site - Murdoch
Query!
Recruitment hospital [3]
0
0
Research Site - Randwick
Query!
Recruitment postcode(s) [1]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [2]
0
0
WA6150 - Murdoch
Query!
Recruitment postcode(s) [3]
0
0
2031 - Randwick
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Kentucky
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New York
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Rhode Island
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Ontario
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Quebec
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Changsha
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Chengdu
Query!
Country [10]
0
0
Georgia
Query!
State/province [10]
0
0
Tbilisi
Query!
Country [11]
0
0
Japan
Query!
State/province [11]
0
0
Chuoku
Query!
Country [12]
0
0
Japan
Query!
State/province [12]
0
0
Kashiwa
Query!
Country [13]
0
0
Japan
Query!
State/province [13]
0
0
Kitaadachi-gun
Query!
Country [14]
0
0
Japan
Query!
State/province [14]
0
0
Kotoku
Query!
Country [15]
0
0
Japan
Query!
State/province [15]
0
0
Nagoya
Query!
Country [16]
0
0
Japan
Query!
State/province [16]
0
0
Osakasayama-shi
Query!
Country [17]
0
0
Malaysia
Query!
State/province [17]
0
0
George Town
Query!
Country [18]
0
0
Malaysia
Query!
State/province [18]
0
0
Johor Bahru
Query!
Country [19]
0
0
Malaysia
Query!
State/province [19]
0
0
Kuala Lumpur
Query!
Country [20]
0
0
Malaysia
Query!
State/province [20]
0
0
Kuala Selangor
Query!
Country [21]
0
0
Malaysia
Query!
State/province [21]
0
0
Kuching
Query!
Country [22]
0
0
Moldova
Query!
State/province [22]
0
0
Chisinau
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Krakow
Query!
Country [24]
0
0
Poland
Query!
State/province [24]
0
0
Warsaw
Query!
Country [25]
0
0
Singapore
Query!
State/province [25]
0
0
Bukit Merah
Query!
Country [26]
0
0
Singapore
Query!
State/province [26]
0
0
Singapore
Query!
Country [27]
0
0
South Korea
Query!
State/province [27]
0
0
Gyeonggi-do
Query!
Country [28]
0
0
South Korea
Query!
State/province [28]
0
0
Seoul
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
Barcelona
Query!
Country [30]
0
0
Spain
Query!
State/province [30]
0
0
Madrid
Query!
Country [31]
0
0
Taiwan
Query!
State/province [31]
0
0
Kaohsiung City
Query!
Country [32]
0
0
Taiwan
Query!
State/province [32]
0
0
Taichung
Query!
Country [33]
0
0
Taiwan
Query!
State/province [33]
0
0
Tainan
Query!
Country [34]
0
0
Taiwan
Query!
State/province [34]
0
0
Taipei
Query!
Country [35]
0
0
Taiwan
Query!
State/province [35]
0
0
Taoyuan
Query!
Country [36]
0
0
United Kingdom
Query!
State/province [36]
0
0
Glasgow
Query!
Country [37]
0
0
United Kingdom
Query!
State/province [37]
0
0
Leeds
Query!
Country [38]
0
0
United Kingdom
Query!
State/province [38]
0
0
London
Query!
Country [39]
0
0
United Kingdom
Query!
State/province [39]
0
0
Oxford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AstraZeneca
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .
Query!
Trial website
https://clinicaltrials.gov/study/NCT06219941
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
AstraZeneca Clinical Study Information Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-877-240-9479
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP)
Query!
When will data be available (start and end dates)?
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Query!
Available to whom?
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://astrazenecagroup-dt.pharmacm.com/DT/Home
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06219941
Download to PDF